tetano
Editor, Senior Moderator
Cardiol Young
. 2023 Jul 6;1-11.
doi: 10.1017/S1047951123001579. Online ahead of print. Multisystem inflammatory syndrome in children: another COVID-19 sequel
Christophe El Rassi[SUP] 1 [/SUP], Rana Zareef[SUP] 2 3 [/SUP], Rawan Honeini[SUP] 2 [/SUP], Christelle Latouf[SUP] 2 [/SUP], Fadi Bitar[SUP] 2 3 [/SUP], Mariam Arabi[SUP] 2 3 [/SUP]
Affiliations
With the rapid expansion of the COVID-19 pandemic, the disease burden and its consequences on the paediatric population has been progressively recognised. Although COVID-19 infection in children presents as asymptomatic to mild illness, instances of hyperinflammation and multi-organ involvement following the viral infection have been described. This condition, known as the multisystem inflammatory syndrome in children (MIS-C), has gained a wide global attention. Despite the global efforts to uncover the disease characteristics and management, a clear pathogenesis and a unified treatment regimen have not been reached yet. This paper tackles the epidemiology of the MIS-C, discusses its suggested pathogenesis, drives through its varying clinical presentations, and evaluates the different treatment regimens employed in managing MIS-C.
Keywords: COVID-19; coronavirus; multisystem inflammatory syndrome in children.
. 2023 Jul 6;1-11.
doi: 10.1017/S1047951123001579. Online ahead of print. Multisystem inflammatory syndrome in children: another COVID-19 sequel
Christophe El Rassi[SUP] 1 [/SUP], Rana Zareef[SUP] 2 3 [/SUP], Rawan Honeini[SUP] 2 [/SUP], Christelle Latouf[SUP] 2 [/SUP], Fadi Bitar[SUP] 2 3 [/SUP], Mariam Arabi[SUP] 2 3 [/SUP]
Affiliations
- PMID: 37409933
- DOI: 10.1017/S1047951123001579
With the rapid expansion of the COVID-19 pandemic, the disease burden and its consequences on the paediatric population has been progressively recognised. Although COVID-19 infection in children presents as asymptomatic to mild illness, instances of hyperinflammation and multi-organ involvement following the viral infection have been described. This condition, known as the multisystem inflammatory syndrome in children (MIS-C), has gained a wide global attention. Despite the global efforts to uncover the disease characteristics and management, a clear pathogenesis and a unified treatment regimen have not been reached yet. This paper tackles the epidemiology of the MIS-C, discusses its suggested pathogenesis, drives through its varying clinical presentations, and evaluates the different treatment regimens employed in managing MIS-C.
Keywords: COVID-19; coronavirus; multisystem inflammatory syndrome in children.